Recent studies have suggested that benzalkonium chloride (BKC), an antimicrobial agent used as a preservativein nasal sprays, lacks deleterious e¡ects onthe nasalciliated epithelium.Otherdata, includingrecent in vivo ¢ndings, suggestthat BKC may, in fact, produce adverse clinical e¡ects on human nasal tissue, including the aggravation of rhinitis medicamentosa.Toxic e¡ects have also been reported. In light of the discrepancy between negative results and studies suggesting no safety concerns, we consider the possibility of problems in the design and methodology of some of the studies and in the interpretation of results.Clearly, further research is warranted to clarify the signi¢cance of con£icting ¢ndings. In the meantime, without conclusive data regarding BKC and the possibility of harmful e¡ects, the use of nasal formulations without BKC might be a reasonable alternative.
INTRODUCTION
Benzalkonium chloride (BKC) is a quarternary ammonium compound commonly used to prevent bacterial contamination and to preserve pharmacological activity in topical aqueous drops and sprays. Although ophthalmic mucositis and contact dermatitis resulting from the presence of BKC in topical solutions have been documented (1, 2) , investigators have recently concluded that inclusion of the preservative BKC in nasal sprays does not yield any adverse biological e¡ects in vivo (3, 4) . In studies conducted in both laboratory animals and perennial allergic rhinitis patients (3, 4) , the nasal mucosa was shown to be largely una¡ected as assessed primarily by morphological indices. However, recent studies concerning the pathophysiology of rhinitis medicamentosa clearly indicate an adverse biological role of BKC in vivo (5^7). These data are consistent with the numerous in vitro studies characterizing the adverse e¡ects of BKC on nasal mucociliary transport and nasal histology (8^15). Thus, the objective of this article is to reassess the hypothesis that BKC lacks deleterious e¡ects in vivo.
STUDIES SHOWING NO DELETERIOUS EFFECTS

In vivo Animal Studies
In a study conducted in laboratory animals, Ainge et al. failed to show any deleterious e¡ects of corticosteroidcontaining nasal sprays on the nasal epithelium (3) . The objective of the study was to examine the e¡ect of repeated exposure of normal cynomolgus monkeys and rats to BKC-containing steroid formulations, namely, £uticasone propionate and beclomethasone dipropionate nasal sprays.
Cynomolgus monkeys were treated with £uticasone propionate (0?05% w/v) containing 0?02% BKC for 28 days (860?1ml day 71 by intra-nasal spray). Rats were treated with beclomethasone dipropionate (0?2%) nasal spray containing 0?01% BKC for 28 days (1h day 71 via inhalation). Control conditions included either a 5% glucose spray for monkeys or air inhalation for rats. At the conclusion of the treatment period, animals were sacri¢ced and the nasal mucosa examined by light microscopy. In addition, nasal mucosal tissues were sectioned for scanning and transmission electron microscopy to allow for counting of ciliary nasal cells and study of ciliary cell ultrastructure.
The number of ciliated cells per mm of turbinate was not di¡erent in either monkeys or rats when the group administered BKC-containing steroid was compared to control. The respiratory epithelia covering the turbinate surface were also unchanged in treated animals. Likewise, no di¡erence in nasal mucosal ultrastructure (i.e. nuclei, mitochondria, rough and smooth endoplasmic reticula, lysosomes, cytoplasmic vacuoles, microvilli, cilia and their basal bodies) was observed. In summary, no changes in morphological features were noted in the presence of BKC.
However, the signi¢cance of these negative ¢ndings may be limited for several reasons (16, 17) . First, the biopsies of the samples were restricted to the turbinate epithelium (i.e. right inferior turbinate, monkeys; intermediate turbinate, rats) and, therefore, the investigators may have failed to detect benzalkonium-induced structural changes in other regions of the nasal mucosa (17) . Other studies have found BKC to be harmful to other regions of the nasal mucosa (16) . Second, the studies were also conducted with inhaled sprays (i.e. metering/atomizing pumps, in monkeys; inhalation chamber using a glass concentric atomizer fed by a peristaltic pump, in rats), which may have lessened the insult accompanied by pressurized sprays. Ainge et al. (3) exposed the subjects to more BKC than typical decongestants usually contain. While the normal amount of sprays administered per nostril per day is 4, the monkeys received 8 sprays per day. The concentrations of BKC administered to the monkeys were lower than patients typically receive (0?01% vs. 0?02%). However, the nasal epithelium of the rats and monkeys was exposed to BKC continuously for 1h a day, which is much greater exposure than patients typically receive. The absence of morphological damage corroborates previous results revealing no damage to ciliated cells in patients receiving £uticasone propionate aqueous nasal spray or beclomethasone dipropionate aqueous nasal spray.
In contrast, di¡erent parts of the nasal bed may have varying reactions to BKC toxicity and di¡erent degrees of contact with the nasal spray (18) . For example, the anterior area of the nasal septum, the tips of the inferior and middle turbinate, and the anterior aspect of a polyp are more directly challenged by the impact of the nasal spray and, therefore, are exposed to greater concentrations of preservative (18) . Third, since adequate controls with BKC alone (i.e. 5% glucose, monkeys; air, rats) were not performed, it is possible that the corticosteroid masked the deleterious e¡ects of BKC. Fourth, this study was strictly structural and did not consider possible adverse functional e¡ects of BKC. Fifth, it is unclear as to whether the results of this animal trial are transferable to humans. In humans, the anterior parts of the nose are the areas where considerable deposition of inhaled substances occurs. Also, the lack of change in morphological features in the presence of BKC may be due to the pH of the solution (3).Van de Donk et al. (9) suggested that reducing the pH of BKC may signi¢cantly decrease ciliary movement of guinea pig trachea. In the study, the duration of ciliary movement decreased from 1?33 h to 1h when the BKC solution pH was reduced from 7?4 to 6?0.
In vivo Human Studies
BKC was also shown to be nontoxic to nasal mucosa in patients with perennial allergic rhinitis in a study by Braatet al. (4) .The objective of this study was to examine the e¡ects of BKC on the human nasal mucosa in a population of patients with perennial allergic rhinitis.
The study consisted of a single-center, double-blind trial of 22 patients with perennial allergic rhinitis who were also allergic to house dust mites (as con¢rmed by skin-prick test). After a 2-week placebo treatment period, patients were randomized to receive one of the following twice daily: a nasal spray of 200 mg £uticasone propionate containing 0?02% BKC, a placebo aqueous spray of 0?02% BKC, or placebo aqueous nasal spray.
Patients were assessed at 2 weekly intervals during treatment and 2 weeks after treatment by anterior rhinoscopy for turbinate swelling, crushing, bleeding, mucosa color and nasal secretions. Saccharine transport time was determined to assess mucociliary clearance. Prior to treatment and 6 weeks after treatment, two nasal biopsies were taken from each patient 2 cm behind the anterior tip of the inferior turbinate for microscopy. Light microscopy was performed to measure mucosal length and the number of ciliated epithelial cells. Scanning electron microscopy was conducted to determine the ratio of ciliated cells to nonciliated cells.Transmission electron microscopy was used to examine the ultrastructure of the ciliated epithelial cells.
An improvement was noted for mucosal color and secretions in the group of patients assigned £uticasone with BKC, but no change was noted with BKC alone. No di¡erence was noted for any of the patient groups with reference to the ciliary transport times assessed at biweekly intervals by the saccharine clearance test. The number of ciliated cells varied widely but was also unchanged between patient groups. Decreased incidence of edema and in£ammatory cell in¢ltration was noted in patients treated with £uticasone, while BKC appeared to have no e¡ect on this parameter.
Despite the existence of some pathological features in all patients studied, transmission and scanning electron microscopy did not show BKC to have adverse e¡ects. Common pathological features observed in biopsies included the presence of numerous cytoplasmic vacuoles, very electron-dense and swollen mitochondria, and swollen smooth endoplasmic reticulum. Importantly, the cilia appeared similar in all treatment groups, with the classic 9+2 con¢guration of microtubules present. Based on scanning electron microscopy, data was marred (i.e. varying number of ciliated cells) by residual mucus. Furthermore, the surface area covered by cilia was una¡ected by BKC.
As noted for the previous study, weaknesses limit the signi¢cance of the Braat study (16, 17) . First, the biopsies of samples were limited to the inferior turbinates and may not re£ect the deposition and subsequent e¡ects on other nasal regions. However, previous studies such as that by Newman et al. (19) demonstrated chief deposition in the anterior part of the nose in10 normal subjects using nasal pump sprays.Within 30 min of administration, a mean 56% of the dose remained at the initial site of deposition, while the remainder (44%) of the dose cleared to the nasopharynx (19) . Second, signi¢cant variation was observed in the patients studied under control conditions, particularly with regard to morphological data, such that any changes ascribed to BKC were di⁄cult to detect. Third, the patient population under study was su¡ering from perennial allergic rhinitis, whereby protection a¡orded by excessive mucus production possibly obscured any adverse biological e¡ects of BKC.This protective e¡ect was observed in a study by Stanley et al. (11) who suggested that the lack e¡ect of BKC on ciliary beat frequency or mucociliary clearance was the result of the e¡ects of nasal mucus.
A third in vivo study by McMahon et al. attempted to determine the immediate and short-term e¡ect of BKC in an intranasal corticosteroid spray on human nasal mucosa in vivo (20) . In this study, the authors assessed mean saccharine clearance time, acoustic rhinometry, and ciliary beat frequency prior to and after 2 weeks of therapy in normal volunteers randomized to receive saline, £uticasone propionate aqueous nasal spray, or placebo. A 10 -min exposure to BKC in 34 subjects led to a signi¢cant increase in the mean clearance time (762?7+ 459 sec) versus that observed with saline alone (620+437 sec). However, a double-blind multi-dose study comparing saline solution, £uticasone propionate plus BKC, and BKC alone, administered for 2 weeks at 2 pu¡s per day, showed no di¡erences in saccharine clearance or in any of the variables tested.
The initial results of the studyöthat the BKC solution caused an immediate increase in mucociliary clearance timeöwere most likely due to ciliary dysfunction resulting from the application of BKC (20) . Although the toxic e¡ects of BKC were not apparent in the multidose study, both the initial test and the 2-week study included only normal individuals; patients su¡ering from rhinitis who had used a topical nasal treatment in the 2 weeks prior to the study were not tested. In patients with rhinitis, it is important to note that the capacity of the mucociliary defense system may be reduced as a result of the disease itself. Patients with rhinitis, therefore, may be more prone to the adverse e¡ects of BKC than normal individuals (12) . Recent studies suggest that the main determinant of nasal mucociliary clearance is ciliary beat frequency (21) . In addition, Graf and Hallen (6) recorded a potentiation of rhinitis medicamentosa in the presence of BKC. However, patients with rhinitis tend to produce more mucus, which can have a protective e¡ect against BKC (11) . Storaas et al. (22) showed that sustained administration of BKC to human nasal mucosa can generate tolerance without adverse e¡ects. Using healthy subjects, Storaas et al. (22) administered isotonic saline and BKC (0?1mgml 71 ) acutely to nasal mucosa. At ¢rst the BKC induced immediate nasal smart or pain (P50?05), but after repeated administrations over 10 days, patients developed tolerance.
STUDIES SHOWING DELETERIOUS EFFECTS
In vivo Animal Studies: Evidence of Squamous Cell Metaplasia
Using BKC as a preservative in corticosteroid-containing nasal sprays administered to rats, Berg et al. demonstrated that BKC may be potentially toxic to the nasal mucosa in vivo (16) . In contrast to the study of Ainge et al. described above (3), the objective of this study was to examine the morphological e¡ects of topical nasal steroids in the presence or absence of BKC in di¡erent parts of the nasal cavities originally covered by histiotypic respiratory ciliated mucosa (16) .
The study was conducted in 30 rats divided into three groups and given one of the following: beclomethasone dipropionate aqueous nasal spray (plus 310 mgml 71 BKC), £unisolide nasal spray (plus 220 mgml 71 BKC), or budesonide (no BKC) aqueous nasal spray. In a separate experimental set-up, two groups of10 animals were treated with either beclomethasone dipropionate or budesonide. The steroid solutions were administered by spray twice daily for 21 days into the right nostril, whereas the left nostril received saline delivered by a micro-pipette. At the conclusion of the treatment period, a careful morphological study was conducted by cutting the nose serially in frontal sections of 4 mm from the anterior and posterior parts of the nose.
The strengths of this study included the ability to: (a) use a rat animal model with respiratory mucosa devoid of respiratory tract disease with a similar structure, function, and metabolism to that found in humans; (b) control the dose and deposition of the drug; (c) investigate the nasal mucosa in total as opposed to focal biopsies; and (d) examine the e¡ect of topical steroids with and without BKC versus controls in the same section (16) .
In response to beclomethasone and £unisolide nasal sprays containing BKC, squamous cell metaplasia was evident primarily in the anterior portion of the nose. Characteristic of these tissues was a reduced epithelial cell height with some pleomorphism. In addition, cilia were rarely found and layers of mucus were absent.
Notably, animals treated with budesonide nasal spray that did not contain BKC exhibited no histological di¡erences as compared to saline controls. A thick, pseudo-strati¢ed epithelium was found on the lateral nasal wall and the septum. Individual cells were characterized as having a tall and columnar phenotype and typically displayed cilia on their apical surface covered with a layer of mucus. The submucosal layer was also una¡ected by budesonide such that the connective tissue, vessels and submucosal glands appeared normal.
Based on these observations and other studies proving steroid compounds to be harmless to respiratory mucosa in vitro (23, 24) , the data suggest that the observed squamous cell hyperplasia was due to the inclusion of BKC in the steroidal nasal sprays.
In vivo Human Studies: Aggravation of Rhinitis Medicamentosa
Graf et al. showed adverse biological e¡ects of BKC in de¢ning the mechanism responsible for rhinitis medicamentosa found in response to overuse of vasoactive decongestants (5^7,24^26). Rhinitis medicamentosa is de¢ned as a condition of nasal hyperreactivity, mucosal swelling, and tolerance that is also found in response to vasoactive decongestants as well as other drugs (24, 27) . In the case of decongestant-induced rhinitis medicamentosa, inclusion of BKC as a preservative has been shown to aggravate rhinitis medicamentosa primarily by increasing nasal swelling.
The e¡ect of BKC as a preservative in a decongestant nasal spray was investigated in a randomized, doubleblind, parallel study with 20 healthy volunteers (5) . The principal aim of the study was to determine whether the use of BKC in oxymetazoline nasal spray exerts any e¡ect on the development of rhinitis medicamentosa.
The subjects were divided into two groups that were treated with oxymetazoline (0?5 mgml 71 ) nasal spray with or without 0.1mg/ml BKC administered three times daily (0?1ml nostril 71 ) for 30 days. Nasal mucosal swelling was determined by rhinostereometry, an optical, direct, non-invasive method via topographic measurement, without manipulating the nasal structures (28) . Of note, this method allows one to distinguish between healthy patients and patients with vasomotor rhinitis who exhibit increased histamine sensitivity (26). Nasal stu⁄ness was estimated on a visual analogue scale (5) .
In healthy volunteers treated with oxymetazoline in the presence of BKC for 30 days, a statistically signi¢cant increase in mucosal swelling (1?14 mm) was found in both inferior conchae. Likewise, both morning and evening nasal stu⁄ness was elevated in healthy volunteers during 4 weeks of treatment with oxymetazoline and BKC (5) . In fact, a signi¢cant increase was detected from the second week of drug treatment.Furthermore, elevated morning and evening stu⁄ness was signi¢cantly greater than that observed in patients treated with oxymetazoline alone as analysed by unpaired t-tests (5) .
It should be noted that patients treated with oxymetazoline alone also exhibited signi¢cant increases in mucosal swelling and nasal stu⁄ness indicative of rhinitis medicamentosaöevents that were aggravated by BKC. Thus, after 30 days of drug treatment, mucosal swelling and mean evening estimated nasal stu⁄ness were signi¢cantly greater in patients administered oxymetazoline with BKC versus oxymetazoline alone.
The detrimental e¡ect of BKC is long-lived, as subsequent treatment of patients with the same combination of drugs led to reduced mucosal swelling in response to BKC after a 3-month period (7) . In this study, the reexposure to drug treatment was limited to 10 days. Only those patients treated with the combination of oxymetazoline and BKC exhibited a signi¢cant increase in nasal stu⁄ness, apparent from the fourth day onward. Mucosal swelling was signi¢cantly increased after the 10 -day reexposure in the oxymetazoline plus BKC group of patients.
In contrast, the patients on oxymetazoline alone failed to show a signi¢cant increase in mucosal swelling. The mucosal swelling found in the oxymetazoline plus BKC group was also signi¢cantly greater than that observed in the oxymetazoline alone group, as determined by an unpaired t-test. Thus, a nasal decongestant spray composed of vasoactive decongestant and BKC has a longterm adverse e¡ect on the nasal mucosa (7) .
A subsequent study by Graf and Hallen demonstrated that BKC alone causes mucosal swelling in healthy volunteers (6) . The objective of this study was to clarify the e¡ects of BKC since earlier studies implicating the preservative through its aggravation of rhinitis medicamentosa and its long-lasting adverse e¡ect on the nasal mucosa were limited to inclusion of the preservative with oxymetazoline (5, 7) .
In this double-blind placebo-controlled study, 30 volunteers were randomized to receive 0?1ml of either 0?5 mgml 71 oxymetazoline nasal spray without BKC, 0?1mgml 71 BKC nasal spray alone, or placebo nasal spray consisting of an aqueous solution of sodium chloride, sodium phosphate, and ethylenediamine tetra-acetic acid. The study drugs were administered three times daily for1month.The variables studied included nasal mucosal swelling, symptom scores of nasal stu⁄ness, and nasal reactivity, as determined by histamine challenge.
BKC did not generate nasal stu⁄ness as shown in the earlier studies for oxymetazoline plus BKC (5) . Instead, the patient group administered oxymetazoline alone showed elevated nasal stu⁄ness from day 14 onward to the completion of the study. Nasal reactivity, as assessed by histamine challenge, was signi¢cantly increased by BKC after 30 days. However, the increase in nasal reactivity was not as pronounced as that found in patients administered nasal sprays containing oxymetazoline alone.
Nevertheless, discrepancy between the recorded nasal mucosal swelling and the estimated stu⁄ness was found in the BKC group, in contrast to the oxymetazoline group.The explanation may be that after several days on oxymetazoline, the subjects adjust to breathing easily through the nose. When the decongestive e¡ect disappears, subjects may experience nasal stu⁄ness without rebound swelling (i.e. a false or exaggerated sensation of nasal stu⁄ness).This may explain why some subjects ¢nd it hard to stop using the decongestants within the recommended time and why they ultimately develop rhinitis medicamentosa.
The most outstanding adverse biological event associated with the administration of BKC involved the swelling of the nasal mucosa after the completion of the treatment. At the end of treatment, a signi¢cant increase in mucosal swelling was found in the BKC group (0?67 mm) as compared to either the oxymetazoline group (0?29 mm) or the placebo group (0?09 mm).
Based on these ¢ndings, it was concluded that BKC aggravates decongestant-induced rhinitis medicamentosa via mucosal swelling (6) . However, a possible confounding factor in this study is that oxymetazoline extends the duration of contact of BKC with the nasal mucosa (29) . Combined with BKC, oxymetazoline is more likely to cause rhinitis medicamentosa (29) .
SUMMARY
The objective of this article was to assess the deleterious e¡ects of BKC in vivo. Previous studies concluding that BKC lacks in vivo e¡ects may have been £awed, limiting the signi¢cance of their ¢ndings. Moreover, the data of Graf and colleagues, showing that in vivo administration of BKC aggravates rhinitis medicamentosa in response to vasoactive decongestant nasal sprays, support the contrary. In fact, Berg and colleagues also demonstrate adverse biological e¡ects on rat respiratory mucosa associated with the use of benzalkonium-containing corticosteroid nasal sprays administered in vivo (16) .
Further studies of BKC-containing corticosteroid nasal sprays in both normal volunteers and patients su¡ering from perennial rhinitis are warranted, particularly with functional correlates. Further study of the acute and chronic adverse biologic e¡ects induced by BKC in patients with rhinitis medicamentosa is also warranted, as well as the role of pH in BKC toxicity. In lieu of these data, the use of formulations of corticosteroid-containing sprays now available that do not include BKC may avert any potential adverse biological e¡ects.
